2-Aryl-Propionic Acids and Derivatives and Pharmaceutical Compositions Containing Them
申请人:Allegretti Marcello
公开号:US20110207785A1
公开(公告)日:2011-08-25
The present invention relates to (R,S) 2-aryl-propionic acids and derivatives, their single enantiomer (S) and to pharmaceutical compositions containing them, which are used in the prevention and treatment of tissue damage due to the exacerbated recruitment of polymorphonucleated neutrophils (PIvTN leukocytes) at inflammation sites. The present invention provides compounds for use in the treatment of transient cerebral ischemia, bullous pemphigo, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and damages caused by ischemia and reperfusion. (Formula (I)
2-ARYL-PROPIONIC ACIDS AND DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
申请人:Dompé S.p.A.
公开号:EP2346841B1
公开(公告)日:2015-01-14
US8624036B2
申请人:——
公开号:US8624036B2
公开(公告)日:2014-01-07
[EN] 2-ARYL-PROPIONIC ACIDS AND DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] ACIDES 2-ARYL-PROPIONIQUES, LEURS DÉRIVÉS ET COMPOSITIONS PHARMACEUTIQUES EN CONTENANT
申请人:DOMPE SPA
公开号:WO2010031835A2
公开(公告)日:2010-03-25
The present invention relates to (R, S) 2-aryl-propionic acids and derivatives, their single enantiomer (S) and to pharmaceutical compositions containing them, which are used in the prevention and treatment of tissue damage due to the exacerbated recruitment of polymorphonucleated neutrophils (PMN leukocytes) at inflammation sites. The present invention provides compounds for use in the treatment of transient cerebral ischemia, bullous pemphigo, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and damages caused by ischemia and reperfusion.
2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them
申请人:Dompe' S.P.A.
公开号:EP2166006A1
公开(公告)日:2010-03-24
The present invention relates to (R,S) 2-aryl-propionic acids and derivatives, their single enantiomer (S) and to pharmaceutical compositions containing them, which are used in the prevention and treatment of tissue damage due to the exacerbated recruitment of polymorphonucleated neutrophils (PMN leukocytes) at inflammation sites.
The present invention provides compounds for use in the treatment of transient cerebral ischemia, bullous pcmphigo, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis and damages caused by ischemia and reperfusion.